FDA Approval
FDA Approves Daraxonrasib (Rasonque) for Advanced Pancreatic Cancer
The FDA has approved daraxonrasib (Rasonque), a once-daily targeted pill that nearly doubled survival compared to standard chemotherapy for patients with previously treated metastatic pancreatic cancer.
Read More →
